| Literature DB >> 32198676 |
Bin-Bin Li1, Zheng-Yang Chen2, Nan Jiang3, Song Guo2, Jia-Qi Yang2, Shao-Bin Chai4, Hong-Feng Yan4, Pei-Ming Sun4, Gang Hu4, Tao Zhang4, Bing-Xin Xu5, Hong-Wei Sun4, Jin-Lian Zhou6, He-Ming Yang4, Yan Cui7.
Abstract
Simulated microgravity can significantly affect various cell types and multiple systems of the human body, such as cardiovascular system, skeletal muscle system, and immune system, and is known to cause anemia and loss of electrolyte and fluids. Epidermal stem cells (EpSCs) were cultured in a rotary cell culture system (RCCS) bioreactor to simulate microgravity. The metabolites of EpSCs were identified by liquid chromatography-mass spectrometry (LC-MS). Compared with normal gravity (NG) group, a total of 57 different metabolites of EpSCs were identified (P < 0.05, VIP > 1), including lipids and lipid-like molecules (51 molecules), amino acids (5 molecules), nucleosides, nucleotides, and analogues (1 molecule). According to the partial least squares discriminant analysis (PLS-DA) score plot, a VIP > 1 and P < 0.05 were obtained for the 57 different metabolites, of which 23 molecules were significantly downregulated and 34 were significantly upregulated in simulated microgravity (SMG) group. These results showed that SMG has a significant impact on different pathways, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis indicated that multiple pathways were involved, mainly the amino acid metabolism pathway, lipid metabolism pathway, membrane transport pathway, and cell growth and death pathways. Thus, the metabolic profile of EpSCs was changed under SMG. Exploring the metabolic profile of EpSCs would be helpful to further understand the growth characteristics of EpSCs under SMG, which will provide a new approach to explore the metabolomics mechanism of stress injury and repair trauma under SMG.Entities:
Keywords: Epidermal stem cells; Metabolism; Metabolism pathway; RCCS; Simulated microgravity
Mesh:
Year: 2020 PMID: 32198676 PMCID: PMC7186248 DOI: 10.1007/s11626-020-00435-8
Source DB: PubMed Journal: In Vitro Cell Dev Biol Anim ISSN: 1071-2690 Impact factor: 2.416
Figure 1.Schematic illustration of our experiment used to culture EpSCs on cytodex-3 microcarriers under normal gravity culture and RCCS. The vessel was installed onto the RCCS rotating in a clockwise direction at a speed of 12 rpm in the first d. After cells adhered to the cytodex-3 microcarriers 24 h later, the rotation speed was adjusted to 22 rpm.
Figure 2.Fifty-seven differential metabolites. KEGG compound classification of 57 differential metabolites, including glycolipids, phospholipids, fatty acids, and amino acids (P < 0.05 and VIP > 1).
Altered metabolites with statistical significance between SMG and NG
| Metabolites | VIP score (VIP > 1.0) | ||
|---|---|---|---|
| Upregulated | 2.0150 | < 0.05 | |
| LysoPC(16:0) | 3.97520 | < 0.05 | |
| LysoPE(18:2(9Z,12Z)/0:0) | 1.20850 | < 0.05 | |
| LysoPC(20:4(8Z,11Z,14Z,17Z)) | 1.54970 | < 0.05 | |
| LysoPC(16:1(9Z)) | 6.72790 | < 0.05 | |
| LysoPC(P-18:0) | 4.23040 | < 0.05 | |
| LysoPC(0:0/18:0) | 6.43030 | < 0.05 | |
| PC(P-15:0/0:0) | 1.60280 | < 0.05 | |
| PC(17:1(9Z)/0:0) | 1.91910 | < 0.05 | |
| PC(16:0/0:0)/PC(16:0/0:0) | 11.6912 | < 0.05 | |
| PC(18:1(9Z)/0:0) | 13.2491 | < 0.05 | |
| PC(14:0/0:0) | 2.66480 | < 0.05 | |
| PC(19:1(9Z)/0:0) | 1.41640 | < 0.05 | |
| PC(20:1(9Z)/0:0) | 2.76320 | < 0.05 | |
| PE(18:1(9Z)/0:0) | 5.18730 | < 0.05 | |
| PE(18:0/0:0) | 2.84110 | < 0.05 | |
| PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:0) | 1.43070 | < 0.05 | |
| PE(16:0/0:0) | 2.01650 | < 0.05 | |
| PE(O-18:0/0:0) | 1.83920 | < 0.05 | |
| PE(P-18:0/0:0) | 2.87990 | < 0.05 | |
| PI(18:0/0:0) | 2.08050 | < 0.05 | |
| PI(18:1(9Z)/0:0) | 1.80560 | < 0.05 | |
| 1-Hexadecyl-glycero-3-phosphate | 2.65970 | < 0.05 | |
| MG(0:0/20:3(11Z,14Z,17Z)/0:0) | 1.45120 | < 0.05 | |
| MG(16:1(9Z)/0:0/0:0) | 1.97220 | < 0.05 | |
| MG(18:1(9Z)/0:0/0:0) | 3.76530 | < 0.05 | |
| 19-Norandrosterone | 1.46090 | < 0.05 | |
| 7-Ketocholesterol | 1.25320 | < 0.05 | |
| 1.63380 | < 0.05 | ||
| Glutathione | 3.17470 | < 0.05 | |
| 1.63560 | < 0.05 | ||
| 2.18430 | < 0.05 | ||
| Arginyl-hydroxyproline | 1.36820 | < 0.05 | |
| 5′-Methylthioadenosine | 3.57950 | < 0.05 | |
| Downregulated | PC(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) | 2.85060 | < 0.05 |
| PC(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) | 1.90810 | < 0.05 | |
| PC(0:0/20:4(5Z,8+A28:F38Z,11Z,14Z)) | 1.00600 | < 0.05 | |
| PC(18:0/20:3(5Z,8Z,11Z)) | 1.34610 | < 0.05 | |
| PE(15:0/22:0) | 1.61560 | < 0.05 | |
| PE(22:4(7Z,10Z,13Z,16Z)/P-16:0) | 3.63830 | < 0.05 | |
| PE(P-18:0/20:4(6E,8Z,11Z,14Z)(5OH[S])) | 3.50460 | < 0.05 | |
| PE(18:0/22:5(4Z,7Z,10Z,13Z,16Z)) | 1.57940 | < 0.05 | |
| PE(15:0/20:0) | 3.08910 | < 0.05 | |
| PE(15:0/24:1(15Z)) | 4.63110 | < 0.05 | |
| PE(16:0/22:4(7Z,10Z,13Z,16Z)) | 3.81120 | < 0.05 | |
| PS(15:0/18:0) | 1.76470 | < 0.05 | |
| PS(18:0/24:0) | 2.09720 | < 0.05 | |
| PS(20:3(8Z,11Z,14Z)/18:0) | 2.67050 | < 0.05 | |
| PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z)) | 1.06960 | < 0.05 | |
| Docosahexaenoic acid | 1.97200 | < 0.05 | |
| Ceramide (d18:1/24:1(15Z)) | 1.80790 | < 0.05 | |
| N-Glycoloylganglioside GM2 | 2.12900 | < 0.05 | |
| N-Palmitoylsphingosine | 1.60520 | < 0.05 | |
| Lactosylceramide (d18:1/12:0) | 2.95220 | < 0.05 | |
| SM(d18:0/18:1(11Z)) | 1.43280 | < 0.05 | |
| SM(d18:1/24:1(15Z)) | 3.18440 | < 0.05 | |
| N-Hexadecanoylsphinganine-1-phosphocholine | 1.46990 | < 0.05 |
VIP, variable importance in the projection
Figure 3.Heat map of 57 differential metabolites. The colorkey above the heat map indicates the expression level of these 57 differential metabolites, and red represents upregulation while green represents downregulation.
Fifty-one lipids and lipid molecules
| Lipid category species | Lipid class | Abbreviation | No. of lipid |
|---|---|---|---|
| Phospholipid | Phosphatidylcholine | PC | 10 |
| Alkenylphosphatidylcholine | PC(P) | 1 | |
| Phosphatidylethanolamine | PE | 10 | |
| Alkylphosphatidylethanolamine | PE(O) | 1 | |
| Lkylphosphatidylethanolamin | PE(P) | 2 | |
| Phosphatidylinositol | PI | 2 | |
| Phosphatidylserine | PS | 4 | |
| 1-Hexadecyl-glycero-3-phosphate | PA | 1 | |
| Sphingolipid | Sphingomyelin | SM | 3 |
| Ceramide | Cer | 2 | |
| Glycosphingolipid | Gcer | 1 | |
| Lactosylceramide | Lcer | 1 | |
| Glycerolipide | Monoacylglycerol | MG | 3 |
| Lysophospholipid | Lysophosphatidylethanolamine | LPE | 1 |
| Lyso-phosphatidylcholine | LPC | 5 | |
| 1 | |||
| Fatty acyls | Docosahexaenoic acid | DHA | 1 |
| Steroids | 19-Norandrosterone | 1 | |
| Steroid derivatives | 7-Ketocholesterol | 1 | |
| Total lipids | 51 |
VIP > 1 and P < 0.05
Fifty-one specific lipids and lipid molecules
| PC | PC(18:1(11Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) |
| PC(20:1(11Z)/22:5(7Z,10Z,13Z,16Z,19Z)) | |
| PC(0:0/20:4(5Z,8+A28:F38Z,11Z,14Z)) | |
| PC(18:0/20:3(5Z,8Z,11Z)) | |
| PC(P-15:0/0:0) | |
| PC(17:1(9Z)/0:0) | |
| PC(16:0/0:0) | |
| PC(18:1(9Z)/0:0) | |
| PC(14:0/0:0) | |
| PC(19:1(9Z)/0:0) | |
| PC(20:1(9Z)/0:0) | |
| PE | PE(15:0/22:0) |
| PE(22:4(7Z,10Z,13Z,16Z)/P-16:0) | |
| PE(P-18:0/20:4(6E,8Z,11Z,14Z)(5OH[S])) | |
| PE(18:0/22:5(4Z,7Z,10Z,13Z,16Z)) | |
| PE(15:0/20:0) | |
| PE(15:0/24:1(15Z)) | |
| PE(16:0/22:4(7Z,10Z,13Z,16Z)) | |
| PE(18:1(9Z)/0:0) | |
| PE(18:0/0:0) | |
| PE(22:5(4Z,7Z,10Z,13Z,16Z)/20:0) | |
| PE(16:0/0:0) | |
| PE(O-18:0/0:0) | |
| PE(P-18:0/0:0) | |
| PI | PI(18:0/0:0) |
| PI(18:1(9Z)/0:0) | |
| PS | PS(15:0/18:0) |
| PS(18:0/24:0) | |
| PS(20:3(8Z,11Z,14Z)/18:0) | |
| PS(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/22:1(13Z)) | |
| PA | 1-Hexadecyl-glycero-3-phosphate |
| SM | SM(d18:0/18:1(11Z)) |
| SM(d18:1/24:1(15Z)) | |
| N-Hexadecanoylsphinganine-1-phosphocholine | |
| Lcer | Lactosylceramide (d18:1/12:0) |
| Cer | Ceramide (d18:1/24:1(15Z)) |
| N-Palmitoylsphingosine | |
| Gcer | N-Glycoloylganglioside GM2 |
| LPC | LysoPC(16:0) |
| LysoPC(20:4(8Z,11Z,14Z,17Z)) | |
| LysoPC(16:1(9Z)) | |
| LysoPC(P-18:0) | |
| LysoPC(0:0/18:0) | |
| LPE | LysoPE(18:2(9Z,12Z)/0:0) |
| MG | MG(0:0/20:3(11Z,14Z,17Z)/0:0) |
| MG(16:1(9Z)/0:0/0:0) | |
| MG(18:1(9Z)/0:0/0:0) | |
| Steroids | 19-Norandrosterone |
| Steroid derivatives | 7-Ketocholesterol C27H44O2 |
| Fatty acyls | Docosahexaenoic acid |
Figure 4.KEGG pathway enrichment analysis. The abscissa represents pathway name, and the ordinate represents enrichment rate, indicating the ratio of the number of metabolites enriched in the pathway to the number of metabolites annotated to the pathway. The larger the ratio, the greater the enrichment degree. Column color gradient indicates the significance of enrichment. The darker the default color is, the more significant the KEGG term is. P value or FDR < 0.001 is marked with ***, P value or FDR < 0.01 is marked with **, and P value or FDR < 0.05 is marked with *.